covid
Buscar en
Progresos de Obstetricia y Ginecología
Toda la web
Inicio Progresos de Obstetricia y Ginecología Tratamiento inmunodepresor en la gestación
Journal Information
Vol. 44. Issue 11.
Pages 468-481 (January 2001)
Share
Share
Download PDF
More article options
Vol. 44. Issue 11.
Pages 468-481 (January 2001)
Full text access
Tratamiento inmunodepresor en la gestación
Immunosuppressive treatment in pregnancy
Visits
5313
B. Sádaba
Corresponding author
bsadaba@unav.es

Correspondencia: Servicio de Farmacología Clínica. Clínica Universitaria de Navarra. Avda. Pío XII, s/n. 31008 Pamplona
, J. Honorato, E. Caballero, E. Cárdenas, E. García-Quetglas, J.R. Azanza
Servicio de Farmacología Clínica. Clínica Universitaria. Facultad de Medicina. Universidad de Navarra
This item has received
Article information
Resumen

En la actualidad son muy numerosos los pacientes en tratamiento inmunodepresor. En mujeres, la necesidad de mantener el tratamiento inmunodepresor para preservar la función del órgano trasplantado añade un factor a considerar durante el embarazo, dado que pueden desencadenarse o agravarse situaciones patológicas asociadas con la gestación o producir efectos teratógenos o tóxicos sobre el feto

En el presente artículo se repasan los diferentes grupos de fármacos inmunodepresores en relación con la gestación

En general, son embarazos asociados con una mayor incidencia de prematuridad y de bajo peso del neonato. Es necesario realizar una vigilancia especial en dos aspectos: por una parte, monitorizar más estrechamente las concentraciones sanguíneas, y por otro lado, es importante vigilar la glucemia y la presión arterial, que puede evolucionar hacia una preeclampsia

De todas formas, no debería suspenderse el tratamiento inmunodepresor, puesto que el riesgo de rechazo del órgano es evidente

Palabras clave:
Gestación
Teratogenia
Inmunosupresión
Abstract

Today there are many patients with immunosupressor therapy. In women, the need to mantain it to preserve the graft and its function, adds a factor to think about it during pregnancy, because pathologycal situation can start or get worse and theratogenic or toxic effects can occurr in the fetus

This article is a review of the several immunosupressor drugs and its relation with pregnancy

Generally, those pregnancies are associated with prematurity and low birth weight. It is necessary a special surveillance for two aspects: first a closer monitorization of blood drug concentrations, on the other hand, it is important to watch out for glucemia and blood pressure to rule out for preeclampsia

Immunosurpressor therapy should not be stopped because of the graft rejection is a high risk

keywords:
Pregnancy
Teratogenicity
Inmunosupressor therapy
Full text is only aviable in PDF
Bibliografía
[1.]
B. Krauer, F. Krauer.
Drug kinetics in pregnancy.
Clin Pharmacokinet, 2 (1977), pp. 167-181
[2.]
T.P. Green, D.L. Mirkin.
Clinical pharmacokinetics: pediatric considerations.
Pharmacokinetic basis for drug treatment, pp. 269-282
[3.]
W.A. Parker.
Effects of pregnancy on pharmacokinetics.
Pharmacokinetic basis for drug treatment, pp. 249-268
[4.]
J.A. Armijo, F.A. Navarro, J. Benítez.
Factores fisiológicos que condicionan la respuesta a los fármacos.
Farmacología humana, pp. 99-121
[5.]
E. Albengres, H. Le Louet, J.P. Tillement.
Immunosuppressive drugs and pregnancy: experimental and clinical data.
Transplant Proc, 29 (1997), pp. 2461-2466
[6.]
G.M. Pacifici, R. Nottoli.
Placental transfer of drugs administered to the mother.
Clin Pharmacokinet, 28 (1995), pp. 235-269
[7.]
J.G.W. Theis, G. Koren.
Maternal and fetal clinical pharmacology.
Avery's drug treatment, 4.a ed, pp. 75-126
[8.]
A. Heikkilä, R. Erkkola.
Review of b-lactam antibiotics in pregnancy. The need for adjustment of dosage schedules.
Clin Pharmacokinet, 27 (1994), pp. 49-62
[9.]
P. Bourget, H. Fernández, H. Bismuth, E. Papiernik.
Transplacental passage of cyclosporine after liver transplantation.
Transplantation, 49 (1990), pp. 663
[10.]
P. Bourget, H. Fernández, C. Delouis.
Accumulation of cyclosporine in the conceptus during the first trimester of pregnancy after liver transplantation.
Transplantation, 51 (1991), pp. 1302-1303
[11.]
A. Jain, R. Venkataramanan, J.J. Fung, J.C. Gartner, J. Lever, V. Balan, et al.
Pregnancy after liver transplantation under tacrolimus.
Transplantation, 64 (1997), pp. 559-565
[12.]
B.M. Barrou, A.C. Gruessner, D.E.R. Sutherland, R.W.G. Grussner.
Pregnancy after pancreas transplantation in the cyclosporine era.
Transplantation, 65 (1998), pp. 524-527
[13.]
V.T. Armenti, G.S. Gentner, J.A. Eisenberg, C.H. McGrory, M.J. Moritz.
National transplantation pregnancy registry: outcomes of pregnancies in lung recipients.
Transplant Proc, 30 (1998), pp. 1528-1530
[14.]
F.R. Pruvot, N. Declerck, A.S. Valat-Rigot, L. Gambiez, V. Canva, M. Labalette, et al.
Pregnancy after liver transplantation: focusing of risk to the mother.
Transplant Proc, 29 (1997), pp. 2470-2471
[15.]
V.T. Armenti, M.J. Moritz, J.M. Davison.
Drug safety issues in pregnancy following transplantation and immunosuppression. Effects and outcomes.
Drug Safety, 19 (1998), pp. 219-332
[16.]
J.S. Serrano, M.I. Serrano, J.N. Rodríguez.
Uso de medicamentos durante el embarazo. Tratado de Medicina Interna.
Medicine, 92 (1991), pp. 3607-3616
[17.]
AHFS 96.
American Hospital Formulary Service. Drug information. Gerald K McEvoy, Pharm D. Bethesda, USA, (1996),
[18.]
K.R. Branch, L.E. Wagoner, C.H. McGrory, J.D. Mannion, J.S. Radomski, M.J. Moritz, et al.
Risk of subsequent pregnancies on mother and newborn in female heart transplant recipients.
J Heart Lung Transplant, 17 (1998), pp. 698-702
[19.]
H.L. Casele, S.A. Laiper.
Association of pregnancy complications and choice of immunosuppressant in liver transplant patients.
Transplantation, 65 (1998), pp. 581-583
[20.]
J.L. Touraine, P. Audra, N. Lefrançois, J.L. Garnier, D. Dargent, X. Martin, et al.
Pregnancy in renal transplant patients: 45 case reports.
Transplant Proc, 29 (1997), pp. 2472-2474
[21.]
C. Delforge, R. Kartheuser, J.F. De Plaen, M. Goenen, C. Hubinont.
Pregnancy after cardiac transplantation.
Transplant Proc, 29 (1997), pp. 2481-2483
[22.]
V.T. Armenti, K.M. Ahlswede, B.A. Ahlswede, J.R. Cater, B.E. Jarrell, M.J. Moritz, et al.
Variables affecting birthweight and graft survival in 197 pregnancies in cyclosporine-treated female kidney transplant recipients.
Transplantation, 59 (1995), pp. 476-479
[23.]
P. Rieu, N. Neyrat, C. Hiesse, B. Charpentier.
Thirty-three pregnancies in a population of 1725 renal transplant patients.
Transplant Proc, 29 (1998), pp. 2459-2460
[24.]
V. Lamarque, M.F. Leleu, C. Monka, P. Krupp.
Analysis of 629 pregnancy outcomes in transplant recipients treated with Sandimmun.
Transplant Proc, 29 (1997), pp. 2480
[25.]
A. Wu, B. Nashan, U. Messner, H.H. Schmidt, H.H. Guenther, S. Niesert, et al.
Outcome of 22 successful pregnancies after liver transplantation.
Clin Transplant, 12 (1998), pp. 454-464
[26.]
N. Rayes, R. Neuhaus, M. David, T. Steinmuller, W.O. Bechstein, P. Neuhaus.
Pregnancies following liver transplantation. How safe are they? A report of 19 cases under cyclosporine A and tacrolimus.
Clin Transplant, 12 (1998), pp. 396-400
[27.]
S. Ourahma, C. Sylla, B. Barrou, C. Mouquet, J. Luciani, M. Tallier, et al.
Future of children of transplanted mothers: results of a multicenter study.
Transplant Proc, 30 (1998), pp. 2808
Copyright © 2001. Sociedad Española de Ginecología y Obstetricia
Download PDF
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos